Drug profile · INN
valproate
EPILIM
valproate (EPILIM) is a succinate semialdehyde dehydrogenase inhibitor. Associated with Alphapharm Pty Ltd.
TGA: approved
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — valproate
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 3
- Data quality
- 0.81
Quick answer
valproate (EPILIM) is a succinate semialdehyde dehydrogenase inhibitor. Associated with Alphapharm Pty Ltd.
Key facts
INN valproate
Brand EPILIM
Mechanism Succinate semialdehyde dehydrogenase inhibitor
Target Succinate-semialdehyde dehydrogenase, mitochondrial
Originator Alphapharm Pty Ltd
Mechanism of action
Succinate semialdehyde dehydrogenase inhibitor
Primary target: Succinate-semialdehyde dehydrogenase, mitochondrial
Approval history
| Authority | Status | Date |
|---|---|---|
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is valproate?
valproate (EPILIM) is a succinate semialdehyde dehydrogenase inhibitor. Associated with Alphapharm Pty Ltd.
What is the brand name for valproate?
EPILIM is a marketed brand name for valproate. Check FDA Drugs@FDA for the current US label holder and prescribing information.